Adaptimmune

Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for cancer. The company was founded in the United Kingdom in 2008 and has research and corporate links to Oxford University and the University of Pennsylvania. Its operating footprint spans the United Kingdom and the United States, with headquarters in Philadelphia and Milton Park. Adaptimmune's therapeutic approach is based on engineering or modifying T cells so that they can recognize cancer-associated targets. The company has concentrated particularly on T-cell receptor therapies, which are designed to direct a patient's immune cells toward antigens expressed by tumor cells. This focus distinguishes Adaptimmune from companies whose principal platforms are antibody medicines, small-molecule drugs, or immune-checkpoint inhibitors. The company's most significant commercial and regulatory milestone came in August 2024, when the United States Food and Drug Administration granted accelerated approval to Tecelra. Tecelra is a T-cell therapy for a rare form of cancer and was described as the first T-cell therapy approved for a solid tumor. The approval represented an important validation of adoptive cellular therapy beyond blood cancers, where cell therapies had previously achieved their most established regulatory successes. Adaptimmune's pipeline has also included letetresgene autoleucel, commonly called lete-cel, an investigational therapy for myxoid and round-cell liposarcoma. In January 2025, the FDA granted lete-cel breakthrough therapy designation for treatment of this disease. Breakthrough therapy designation is a regulatory development status intended to facilitate interaction between a sponsor and the FDA during development of a medicine that may offer substantial improvement over available treatment options; it is not itself marketing authorization. In July 2025, Adaptimmune announced a definitive agreement to sell Tecelra, lete-cel, and the preclinical uza-cel program to US WorldMeds for $55 million. The transaction concerned the named therapies and program assets rather than a change in the company's historical identity. It marked a strategic shift in the ownership and development path of several of Adaptimmune's principal cell-therapy assets. Adaptimmune's brand is therefore associated with translational cancer immunology, engineered T-cell receptor therapies, and the effort to extend cellular immunotherapy into solid tumors. Its history combines academic collaboration, biotechnology development, regulatory advancement, and later portfolio-asset monetization. Detailed information about its current executive leadership, ownership structure, listing status, and broader commercial operations is not established in the supplied reference material.

Adaptimmune was established in the United Kingdom in 2008, with connections to Oxford University and the University of Pennsylvania. From its formation, the company concentrated on T-cell therapies directed against cancer. Its scientific and business model centered on adapting immune cells to identify tumor-associated targets, with particular attention to engineered T-cell receptor approaches and the challenge of treating solid tumors. The company developed an international operating presence, maintaining locations in the United Kingdom and the United States. Its headquarters are associated with Milton Park in Oxfordshire and Philadelphia, reflecting the academic and biotechnology relationships underlying its development. Rather than positioning itself as a broad pharmaceutical manufacturer, Adaptimmune built its identity around specialized cellular-immunotherapy research and clinical development. A major turning point occurred in August 2024, when the FDA granted accelerated approval to Tecelra. The product was approved for a rare cancer indication and became notable as the first T-cell therapy approved for a solid tumor. This milestone extended the regulatory reach of T-cell treatment beyond the blood-cancer settings in which cellular therapies had previously been most prominent. It also gave Adaptimmune a prominent role in the emerging effort to apply engineered immune-cell treatments to solid tumors. Adaptimmune continued to advance lete-cel, also known as letetresgene autoleucel, for myxoid and round-cell liposarcoma. In January 2025, the FDA granted the program breakthrough therapy designation for this treatment setting. The designation supported closer regulatory engagement but did not constitute final approval. The company's reported portfolio also included uza-cel, which remained preclinical in the supplied reference material. In July 2025, Adaptimmune announced a definitive agreement with US WorldMeds for the sale of Tecelra, lete-cel, and the preclinical uza-cel program. The reported consideration was $55 million. This transaction represented a significant portfolio and strategy decision, transferring several important cell-therapy assets to another company while changing the ownership pathway for products associated with Adaptimmune's principal development efforts. The available reference material does not provide a complete account of Adaptimmune's executive history, financing history, public-market status, clinical-trial results, manufacturing network, or post-transaction operating strategy. Those areas require additional authoritative sources before they can be described reliably.

1. 2025Lete-cel receives breakthrough therapy designation

   The FDA granted breakthrough therapy designation to letetresgene autoleucel for myxoid and round-cell liposarcoma.

   Source
2. 2025Portfolio assets agreed for sale to US WorldMeds

   Adaptimmune announced an agreement to sell Tecelra, lete-cel, and the preclinical uza-cel program to US WorldMeds for $55 million.

   Source
3. 2024Tecelra receives accelerated approval

   The FDA granted accelerated approval to Tecelra for a rare cancer indication, making it the first T-cell therapy approved for a solid tumor.

   Source
4. 2008Company founded in the United Kingdom

   Adaptimmune was founded in the UK with links to Oxford University and the University of Pennsylvania, beginning its work in cancer-directed T-cell therapies.

   Source

A specialist cancer-immunotherapy company focused on engineered T-cell therapies, particularly treatments intended to recognize and attack solid tumors.

• TecelraEngineered T-cell therapy2024

  Tecelra is Adaptimmune's cancer-directed T-cell therapy that received accelerated approval from the U.S. Food and Drug Administration in August 2024 for a rare cancer indication. It is notable as the first T-cell therapy approved for use against a solid tumor, an area historically more difficult for cellular immunotherapies than blood cancers. The supplied reference material does not specify the full prescribing indication, clinical regimen, or commercial status beyond the FDA approval and its later inclusion in the proposed sale to US WorldMeds.

• Letetresgene autoleucel (lete-cel)Investigational engineered T-cell therapy

  Letetresgene autoleucel, commonly called lete-cel, is an investigational T-cell therapy developed for myxoid and round-cell liposarcoma. In January 2025, the FDA granted the program breakthrough therapy designation for this treatment setting. The designation indicates a pathway for enhanced regulatory interaction during development, but it is not marketing approval. Lete-cel was included in Adaptimmune's announced 2025 asset-sale agreement with US WorldMeds.

• Uza-celPreclinical engineered T-cell therapy

  Uza-cel was identified in the supplied reference material as a preclinical Adaptimmune program. It was included with Tecelra and lete-cel in the definitive agreement announced in July 2025 for transfer to US WorldMeds. Further information about its target, indication, development stage, or scientific design is not established by the available material.

• 2025Sale of Tecelra, lete-cel, and uza-cel to US WorldMedsM&A

  Adaptimmune had developed a portfolio centered on engineered T-cell therapies, including the approved Tecelra, the investigational lete-cel program, and preclinical uza-cel.

  What changed. The company announced a definitive agreement to sell Tecelra, lete-cel, and uza-cel to US WorldMeds for $55 million.

  Aftermath. The agreement transferred ownership and development responsibility for the named assets to US WorldMeds. The supplied material does not establish the agreement's closing date or its broader effect on Adaptimmune's remaining business.

  Transaction value. $55 million announced consideration (July 2025)

  Source

• 2025Lete-cel receives FDA breakthrough therapy designation

  The FDA granted breakthrough therapy designation to Adaptimmune's letetresgene autoleucel, or lete-cel, for the treatment of myxoid and round-cell liposarcoma.

  RegulationProduct generation
  Source
• 2025Adaptimmune agrees to sell Tecelra and related programs to US WorldMeds

  Adaptimmune announced a definitive agreement under which US WorldMeds would acquire Tecelra, lete-cel, and the preclinical uza-cel program for $55 million.

  M&A
  Source
• 2024FDA grants accelerated approval to Tecelra

  The U.S. Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra for a rare cancer indication. The therapy was identified as the first T-cell therapy approved for use against a solid tumor.

  Product launchRegulation
  Source

1. Adaptimmune
2. Adaptimmune corporate website